GSK plc (NYSE:GSK) Receives $43.25 Consensus PT from Analysts

GSK plc (NYSE:GSK) has received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $43.25.

A number of research firms have commented on GSK. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Friday. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Insider Buying and Selling

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. FMR LLC lifted its stake in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Primecap Management Co. CA increased its holdings in GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after buying an additional 1,773,020 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of GSK in the second quarter worth about $52,487,000. Fisher Asset Management LLC raised its position in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its stake in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK opened at $33.43 on Friday. GSK has a 12 month low of $32.83 and a 12 month high of $45.92. The stock has a fifty day moving average price of $35.75 and a 200-day moving average price of $38.99. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a market cap of $69.29 billion, a PE ratio of 21.71, a P/E/G ratio of 1.54 and a beta of 0.64.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a $0.3928 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is presently 98.70%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.